In a report issued on August 3, Luca Issi from RBC Capital maintained a Hold rating on Editas Medicine (EDIT – Research Report), with a price target of $40.00. The company’s shares closed last Friday at $19.42, close to its 52-week low of $9.59.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -11.2% and a 38.9% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Editas Medicine is a Hold with an average price target of $21.00, which is a 12.8% upside from current levels. In a report issued on August 3, Stifel Nicolaus also maintained a Hold rating on the stock with a $17.00 price target.
The company has a one-year high of $73.03 and a one-year low of $9.59. Currently, Editas Medicine has an average volume of 1.77M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Read More on EDIT: